ArticleAmerican journal of translational research2025
CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paraspeckle-Mediated Integration of Nuclear RNA Regulation in Skeletal Homeostasis and Pathological Disorder.Calcified tissue international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCCCTC-binding factor (CTCF) is a candidate tumor regulatory gene that encodes multifunctional transcription factors. While its role in various cancers has been studied, its function and mechanism in osteosarcoma were uncertain. Previous studies have identified splicing factor proline and glutamine-rich (SFPQ) as an oncogene in osteosarcoma. Bioinformatic analysis suggested that CTCF may regulate SFPQ transcriptionally. This study aimed to elucidate the role of CTCF in osteosarcoma and explore its possible regulatory relationship with SFPQ.
methodsPotential transcription factors of SFPQ were identified using an online transcription factor analysis database. The expression levels of CTCF in osteosarcoma cells were assessed using quantitative real-time PCR (qRT-PCR) and western blotting (WB). The effect of CTCF and SFPQ on osteosarcoma cell behavior was evaluated through cell function assays, dual-luciferase reporter assays, and rescue experiments.
resultsDatabase analyses (hTFtarget and GEPIA2) indicated a moderate correlation between CTCF and SFPQ. qRT-PCR and WB results confirmed significant CTCF expression in osteosarcoma cells. Overexpression of CTCF enhanced cell proliferation, migration, and invasion. Furthermore, CTCF was found to bind to the promoter region of SFPQ, leading to its upregulation. Rescue experiments demonstrated that SFPQ knockdown attenuated the oncogenic effects of CTCF overexpression.
conclusionsCTCF functions as an oncogene in osteosarcoma by positively regulating SFPQ expression, thereby promoting the malignant properties of osteosarcoma cells. These findings suggest that targeting the CTCF-SFPQ axis may be a therapeutic strategy for osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.